IGF1R (Ab-1161) Antibody

Advanced Research Questions

• How does phosphorylation at Y1161 affect IGF1R signaling compared to other phosphorylation sites?

  Phosphorylation of IGF1R at Y1161 occurs within the activation loop of the kinase domain and plays a critical role in receptor activation and downstream signaling. While Y1161 is important, it functions in conjunction with other key phosphorylation sites (Y1158, Y1162, Y1163) in the activation loop. Research indicates that sequential phosphorylation occurs during receptor activation, with Y1161 phosphorylation contributing to conformational changes that enhance kinase activity .

  Comparative phosphorylation studies have shown that:

  Phosphorylation Site	Primary Role	Downstream Effects
  Y1161	Receptor activation	PI3K-AKT pathway activation
  Y1158/Y1162/Y1163 (triple)	Full kinase activation	Enhanced catalytic activity
  Y1346	Recruitment of signaling proteins	Ras-MAPK pathway activation
  Y1131	Conformational changes	Substrate recognition

  When investigating specific pathways, researchers should consider using antibodies against multiple phosphorylation sites to comprehensively assess IGF1R activation status .

• What are the methodological considerations for detecting IGF1R phosphorylation in tumor samples?

  Detection of IGF1R phosphorylation in tumor samples requires careful consideration of several methodological factors:

  1. Tissue preservation: Phosphorylation status can be rapidly lost during tissue processing. Use flash-freezing or phosphatase inhibitors immediately upon tissue collection.

  2. Extraction protocols: For optimal phosphoprotein detection, use lysis buffers containing phosphatase inhibitors (sodium orthovanadate, sodium fluoride, β-glycerophosphate) and protease inhibitors.

  3. Sample handling: Process samples at 4°C and minimize time between tissue collection and analysis.

  4. Antigen retrieval for IHC: For formalin-fixed, paraffin-embedded tissues, optimize antigen retrieval methods (heat-induced epitope retrieval with citrate buffer, pH 6.0, or EDTA buffer, pH 8.0).

  5. Signal amplification: For low abundance phospho-proteins, consider using signal amplification methods such as tyramide signal amplification.

  6. Quantification: Use image analysis software for objective quantification of staining intensity in IHC or IF applications.

  In triple-negative breast cancer research, IGF1R phosphorylation detection has been successfully implemented using the above considerations, revealing correlations between phospho-IGF1R levels and angiogenesis markers like VEGF and HIF-1α .

• How can IGF1R (Ab-1161) Antibody be used to investigate the cross-talk between IGF1R and other receptor tyrosine kinases?

  To investigate cross-talk between IGF1R and other receptor tyrosine kinases (RTKs), several methodological approaches using IGF1R (Ab-1161) Antibody can be employed:

  1. Co-immunoprecipitation: Use IGF1R (Ab-1161) Antibody to immunoprecipitate IGF1R complexes, followed by Western blotting for other RTKs to identify physical interactions. This approach has been used to demonstrate interactions between IGF1R and HER2 in trastuzumab-resistant cancer cells .

  2. Dual immunofluorescence staining: Combine IGF1R (Ab-1161) Antibody with antibodies against other RTKs (EGFR, HER2) to assess co-localization using confocal microscopy.

  3. Sequential immunoblotting: Probe membranes first with IGF1R (Ab-1161) Antibody, then strip and re-probe with antibodies against other phosphorylated RTKs to compare activation patterns.

  4. Inhibitor studies: Treat cells with specific inhibitors of one RTK pathway and assess effects on IGF1R phosphorylation using IGF1R (Ab-1161) Antibody.

  5. siRNA knockdown experiments: Knockdown one RTK using siRNA and evaluate changes in IGF1R phosphorylation status.

  Research using these approaches has revealed significant cross-talk between IGF1R and HER2/EGFR pathways in cancer cells, with implications for resistance to targeted therapies .

• What are the considerations for using IGF1R (Ab-1161) Antibody in multiplexed phosphoprotein detection assays?

  Multiplexed phosphoprotein detection with IGF1R (Ab-1161) Antibody requires careful optimization:

  1. Antibody compatibility: Ensure compatibility of IGF1R (Ab-1161) Antibody with other primary antibodies based on host species, isotype, and detection systems. Ideally, antibodies should be from different species or use different isotypes.

  2. Sequential staining protocols: For IHC/IF multiplexing, establish a sequential staining protocol with complete elution/stripping between rounds or use spectral unmixing techniques.

  3. Fluorophore selection: Choose fluorophores with minimal spectral overlap when performing multiplexed IF. IGF1R (Ab-1161) Antibody can be custom-conjugated with various fluorophores including AF488, AF555, AF647, etc. .

  4. Validation of multiplexed signals: Validate multiplexed signals against single-stained controls to ensure specificity and lack of steric hindrance.

  5. Image acquisition parameters: Optimize image acquisition parameters to avoid bleed-through and photobleaching.

  6. Data normalization: Implement appropriate normalization methods to account for variations in antibody affinities and detection sensitivities.

  Multiplexed approaches allow simultaneous detection of phospho-IGF1R along with downstream signaling molecules like phospho-AKT and phospho-ERK, providing comprehensive pathway activation data in a single sample .

• How can IGF1R (Ab-1161) Antibody be utilized in studying the role of IGF1R in therapy resistance mechanisms?

  To investigate IGF1R's role in therapy resistance, researchers can implement several strategies with IGF1R (Ab-1161) Antibody:

  1. Time-course analysis: Monitor changes in IGF1R phosphorylation at different time points during treatment with therapeutic agents using Western blotting with IGF1R (Ab-1161) Antibody.

  2. Comparative analysis of sensitive vs. resistant models: Compare IGF1R phosphorylation status in therapy-sensitive and therapy-resistant cell lines or patient-derived xenografts using IHC or Western blotting.

  3. Combination treatment studies: Evaluate IGF1R phosphorylation in response to combination therapies targeting IGF1R and other pathways.

  4. Correlation with clinical outcomes: In clinical samples, correlate IGF1R phosphorylation status with response to therapy and patient outcomes.

  Research utilizing these approaches has demonstrated that increased IGF1R phosphorylation contributes to acquired resistance to trastuzumab in ovarian cancer models. In one study, an anti-IGF1R monoclonal antibody (LMAb1) restored sensitivity to trastuzumab in resistant cells by inhibiting IGF1R activation and downstream MAPK and AKT pathway transduction .

• What methodological approaches can be used to quantify IGF1R activation in response to hypoxia or other microenvironmental stressors?

  Quantifying IGF1R activation in response to microenvironmental stressors requires specialized protocols:

  1. Hypoxia chambers: Culture cells in controlled hypoxia chambers (1-5% O₂) for defined time periods before harvesting for phospho-IGF1R analysis.

  2. Hypoxia-mimetic agents: Treat cells with hypoxia-mimetic agents like cobalt chloride (CoCl₂) or deferoxamine (DFO) as alternative approaches.

  3. Co-staining approaches: Perform co-staining of phospho-IGF1R with hypoxia markers (HIF-1α, CA9) to correlate receptor activation with hypoxic regions.

  4. Quantitative image analysis: Implement quantitative image analysis of immunofluorescence or IHC staining to measure phospho-IGF1R intensity as a function of distance from hypoxic regions or blood vessels.

  5. Live-cell imaging: Develop live-cell imaging approaches using fluorescently tagged IGF1R to monitor receptor trafficking and clustering in real-time during hypoxia.

  Research has shown that hypoxia induces IGF1R activation, which in turn regulates HIF-1α expression and VEGF production, establishing a feedback loop that promotes angiogenesis in cancer . Studies in triple-negative breast cancer have demonstrated that IGF1R phosphorylation increases under hypoxic conditions, correlating with increased expression of HIF-1α and VEGF, and this pathway can be modulated by treatments such as melatonin .

• How can phosphorylation-specific antibodies like IGF1R (Ab-1161) Antibody be used in combination with phosphoproteomics for comprehensive pathway analysis?

  Integrating phospho-specific antibodies with phosphoproteomics offers comprehensive pathway insights:

  1. Validation of phosphoproteomics data: Use IGF1R (Ab-1161) Antibody to validate specific phosphorylation events identified in mass spectrometry-based phosphoproteomics.

  2. Enrichment strategies: Employ IGF1R (Ab-1161) Antibody for immunoprecipitation to enrich IGF1R and its interacting partners prior to phosphoproteomic analysis.

  3. Targeted phosphoprotein analysis: Complement global phosphoproteomics with targeted analysis of IGF1R and key pathway components using antibody-based methods.

  4. Temporal dynamics studies: Use antibody-based detection to define the temporal sequence of phosphorylation events following IGF1R activation, informing computational models of signaling dynamics.

  5. Spatial information integration: Combine phosphoproteomics data with spatial information from immunofluorescence using IGF1R (Ab-1161) Antibody to understand compartment-specific signaling.

  A study investigating miRNA regulation of the PI3K/Akt signaling pathway in colorectal carcinogenesis employed this integrated approach, using IGF1R (Ab-1161) antibody to validate phosphoproteomic findings and establish connections between miRNA regulation and IGF1R phosphorylation status .

• What are the methodological considerations for evaluating IGF1R phosphorylation in circulating tumor cells or liquid biopsies?

  Detecting phospho-IGF1R in circulating tumor cells (CTCs) or liquid biopsies presents unique challenges:

  1. Rapid fixation protocols: Develop and implement rapid fixation protocols to preserve phosphorylation status during CTC isolation.

  2. Microfluidic approaches: Utilize microfluidic platforms for CTC capture followed by on-chip immunostaining for phospho-IGF1R.

  3. Multiplexed CTC characterization: Combine phospho-IGF1R detection with other markers (cytokeratins, CD45, other RTKs) to comprehensively characterize CTCs.

  4. Single-cell analysis: Implement single-cell Western blotting or mass cytometry (CyTOF) approaches to measure phospho-IGF1R in individual CTCs.

  5. Exosome analysis: Develop methods to detect phospho-IGF1R in tumor-derived exosomes as an alternative liquid biopsy approach.

  6. Digital PCR correlation: Correlate phospho-IGF1R protein levels with IGF1R mutation or amplification status detected by digital PCR in circulating tumor DNA.

  While these approaches are technically challenging, they offer the potential for non-invasive monitoring of IGF1R pathway activation during treatment and disease progression. Preliminary studies have demonstrated feasibility of detecting phosphorylated RTKs in CTCs, suggesting potential application for phospho-IGF1R detection.